Pretreating Pam3CysSK4–TLR2 ligand (PAM) stimulated sarcoidosis AMs or PBMCs with a combination of IL-1 receptor-associated kinase (IRAK) 1/4 inhibitor and gefitinib (a non-selective RIPK2 inhibitor, vide infra) led to the reduction of IL-1β, IL-6 and INF-α productions. The gene discussed is RIPK2; the disease is sarcoidosis.